7月10日,国家药品监督管理局(NMPA)官网显示,亚盛医药利沙托克拉片(APG-2575)的新药上市申请已获批准,用于治疗难治或复发性(R/R)慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)。APG-2575是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂,通过选择性抑制Bcl-2蛋白,恢复癌细胞的正常凋亡过程,从而达到治疗肿瘤的目的。APG-2575是全球第二个、中国首个看到明确疗效...
Source Link7月10日,国家药品监督管理局(NMPA)官网显示,亚盛医药利沙托克拉片(APG-2575)的新药上市申请已获批准,用于治疗难治或复发性(R/R)慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)。APG-2575是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂,通过选择性抑制Bcl-2蛋白,恢复癌细胞的正常凋亡过程,从而达到治疗肿瘤的目的。APG-2575是全球第二个、中国首个看到明确疗效...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.